boc-(O-benzyl)-L-hydroxyproline | 40350-83-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: boc-(O-benzyl)-L-hydroxyproline
• 英文别名: Boc-Hyp(OBzl)-OH；Boc-Hyp(Bzl)-OH；Boc-Hyp(OBzl)；N-α-tert-butoxycarbonyl-O-benzyl-L-4-hydroxyproline；trans-N-t-butoxycarbonyl-4-benzyloxy-L-proline；L-N(tert.-butoxycarbonyl)-4-benzyloxy-proline；(2S)-1-[(2-methylpropan-2-yl)oxycarbonyl]-4-phenylmethoxypyrrolidine-2-carboxylic acid
• CAS: 40350-83-2；54631-81-1；54631-82-2
• 化学式: C₁₇H₂₃NO₅
• 分子量: 321.373
• InChiKey: DGIGGVANZFKXLS-KZUDCZAMSA-N

物化性质

• 沸点：
  461.3±45.0 °C(Predicted)
• 密度：
  1.21±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  23
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  76.1
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  boc-(O-benzyl)-L-hydroxyproline 在 palladium on activated charcoal 盐酸 、 N-羟基丁二酰亚胺 、 氢气 、 溶剂黄146 、 三乙胺 、 N,N'-二环己基碳二亚胺 作用下， 以 1,4-二氧六环 、 甲醇 、 二氯甲烷 为溶剂， 反应 48.0h， 生成 Arg-Tyr-Leu-Hyp-Thr
  参考文献：
  名称：

  Konopinska, Danuta; Bartosz-Bechowski, Hubert; Rosinski, Grzegorz, Bulletin of the Polish Academy of Sciences: Chemistry, 1993, vol. 41, # 1, p. 27 - 40

  摘要：

  DOI：

文献信息

• Inhibitors of protein isoprenyl transferases
  申请人：University of Pittsburgh

  公开号：US06221865B1

  公开（公告）日：2001-04-24

  Compounds having the formula or a pharmaceutically acceptable salt thereof wherein R1 is (a) hydrogen, (b) loweralkyl, (c) alkenyl, (d) alkoxy, (e) thioalkoxy, (f) halo, (g) haloalkyl, (h) aryl-L2—, and (i) heterocyclic-L2—; R2 is selected from (a) (b) —C(O)NH—CH(R14)—C(O)OR15, (d) —C(O)NH—CH(R14)—C(O)NHSO2R16, (e) —C(O)NH—CH(R14)-tetrazolyl, (f) —C(O)NH-heterocyclic, and (g) —C(O)NH—CH(R14)—C(O)NR17R18; R3 is substituted or unsubstituted heterocyclic or aryl, substituted or unsubstituted cycloalkyl or cycloalkenyl,  and —P(W)RR3RR3′; R4 is hydrogen, lower alkyl, haloalkyl, halogen, aryl, arylakyl, heterocyclic, or (heterocyclic)alkyl; L1 is absent or is selected from (a) —L4—N(R5)—L5—, (b) —L4—O—L5—, (c) —L4—S(O)n—L5—(d) —L4—L6—C(W)—N(R5)—L5—, (e) —L4—L6—S(O)m—N(R5)—L5—, (f) —L4—N(R5)—C(W)—L7—L5—, (g) —L4—N(R5)—S(O)p—L7—L5—, (h) optionally substituted alkylene, (i) optionally substituted alkenylene, (j) optionally substituted alkynylene (k) a covalent bond, (l) and (m) are inhibitors of protein isoprenyl transferases. Also disclosed are protein isoprenyl transferase inhibiting compositions and a method of inhibiting protein isoprenyl transferases.

  具有以下化学式或其药用盐的化合物，其中R1为(a)氢，(b)较低的烷基，(c)烯基，(d)烷氧基，(e)硫代烷氧基，(f)卤素，(g)卤代烷基，(h)芳基-L2—，和(i)杂环-L2—；R2从(a)(b)—C(O)NH—CH(R14)—C(O)OR15，(d)—C(O)NH—CH(R14)—C(O)NHSO2R16，(e)—C(O)NH—CH(R14)-四唑基，(f)—C(O)NH-杂环，和(g)—C(O)NH—CH(R14)—C(O)NR17R18中选择；R3为取代或未取代的杂环或芳基，取代或未取代的环烷基或环烯基，和—P(W)RR3RR3′；R4为氢，较低烷基，卤代烷基，卤素，芳基，芳基烷基，杂环，或(杂环)烷基；L1不存在或从(a)—L4—N(R5)—L5—，(b)—L4—O—L5—，(c)—L4—S(O)n—L5—，(d)—L4—L6—C(W)—N(R5)—L5—，(e)—L4—L6—S(O)m—N(R5)—L5—，(f)—L4—N(R5)—C(W)—L7—L5—，(g)—L4—N(R5)—S(O)p—L7—L5—，(h)可选择取代的烷基，(i)可选择取代的烯基，(j)可选择取代的炔基，(k)共价键，(l)和(m)是蛋白异戊二烯基转移酶的抑制剂。还公开了蛋白异戊二烯基转移酶抑制组合物和抑制蛋白异戊二烯基转移酶的方法。
• Compounds having cholecystokinin and gastrin antagonistic properties
  申请人：Rhone-Poulenc Rorer Pharmaceuticals Inc.

  公开号：US05340801A1

  公开（公告）日：1994-08-23

  This invention relates to N-arylcarbamoyl proline analogues which are useful as cholecystokinin and gastrin antagonists, to pharmaceutical compositions including such proline analogues, and to their use in preventing or treating cholecystokinin or gastrin related disorders.

  这项发明涉及N-芳基氨基甲酰脯氨酸类似物，可用作胆囊收缩素和胃泌素拮抗剂，包括这种脯氨酸类似物的药物组合物，以及它们在预防或治疗与胆囊收缩素或胃泌素有关的疾病中的应用。
• Studies on heart. XXIII. Distribution of (1-14C) acetamidino-antiarrhythmic peptide (14C-AAP) in mice.
  作者：SHIGERU AONUMA、YASUHIRO KOHAMA、TOSHITAKE MAKINO、IKUFUMI YOSHITAKE、KUNIHIRO HATTORI、KEIKO MORIKAWA、YASUKO WATANABE

  DOI：10.1248/cpb.31.612

  日期：——

  The distribution of [1-14C] acetamidino-antiarrhythmic peptide (14C-AAP) in mice was studied by direct counting and whole-body autoradiography. Intravenously injected 14C decreased rapidly in blood during 1 to 20 min and gradually during 20 to 180 min. At 180 min 68% of the radioactivity had appeared in the urine. At 60 min unmetabolized 14C-AAP was present in the urine. At 1 min the radioactivity was highest in the kidney, followed by the lung, liver, and myocardium in that order. Radioactivity increased in the kidney and myocardium during 1 to 6 min, while the radioactivity in the lung and liver decreased rapidly from 1 to 60 min. Autoradiograms revealed that at 6 min after injection (i.v.) the highest radioactivities were seen in the kidney, urine, heart, lung, submaxillary gland, bone and gut wall. No radioactivity was present in the brain, spinal cord, gut contents or fetus. At 20 to 60 min the radioactivity levels in the organs were much less than those seen at 6 min, except for the kidney and urine. In mice orally given 14C-AAP, the maximum plateau levels of radioactivity were found in the myocardium (0.04% of dose) and blood (2.5%) at 40 to 120 min. In serum at 60 min, 14C-AAP was still present in the original molecular form, unbound to macromolecules. Thus, 14C-AAP accumulates in the myocardium of the target organ for a short time immediately after injection (i.v.), corresponding to the period of the QTc interval prolongation by AAP. 14C-AAP does not accumulate for long in any organ except for the kidney, and is largely excreted in urine within 60 min.

  通过直接计数和全身自动放射成像技术研究了[1-14C]乙酰氨基抗心律失常肽（14C-AAP）在小鼠体内的分布。静脉注射14C后，血液中的放射性在1至20分钟内迅速下降，并在20至180分钟内逐渐下降。180分钟时，68%的放射性出现在尿液中。60分钟时，尿液中存在未代谢的14C-AAP。1分钟时，肾脏中的放射性最高，其次是肺、肝和心肌。1至6分钟时，肾脏和心肌中的放射性增加，而肺和肝中的放射性在1至60分钟内迅速下降。自动放射成像显示，注射（静脉注射）后6分钟，肾脏、尿液、心脏、肺、颌下腺、骨骼和肠壁中的放射性最高。大脑、脊髓、肠道内容物或胎儿中没有放射性。20至60分钟时，除肾脏和尿液外，器官中的放射性水平远低于6分钟时的水平。在小鼠口服14C-AAP后，40至120分钟时，心肌（剂量的0.04%）和血液（2.5%）中的放射性达到最高水平。60分钟时，血清中的14C-AAP仍以原始分子形式存在，未与大分子结合。因此，注射（静脉注射）后，14C-
• Inhibitors of interleukin-1 beta converting enzyme
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US20020099042A1

  公开（公告）日：2002-07-25

  The present invention relates to novel classes of compounds which are inhibitors of interleukin-1&bgr; converting enzyme. The ICE inhibitors of this invention are characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting ICE activity and consequently, may be advantageously used as agents against interleukin-1 mediated diseases, including inflammatory diseases, autoimmune diseases and neurodegenerative diseases. This invention also relates to methods for inhibiting ICE activity and methods for treating interleukin-1 mediated diseases using the compounds and compositions of this invention.

  本发明涉及一种新型化合物类别，其为白细胞介素-1β转化酶抑制剂。本发明的ICE抑制剂具有特定的结构和物理化学特征。本发明还涉及包含这些化合物的制药组合物。本发明的化合物和制药组合物特别适用于抑制ICE活性，因此可以优势地用作对白细胞介素-1介导的疾病，包括炎症性疾病、自身免疫疾病和神经退行性疾病的治疗剂。本发明还涉及使用本发明的化合物和组合物抑制ICE活性的方法和治疗白细胞介素-1介导疾病的方法。
• INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME
  申请人：Bemis Guy W.

  公开号：US20120238749A1

  公开（公告）日：2012-09-20

  The present invention relates to novel classes of compounds which are inhibitors of interleukin-1β converting enzyme. The ICE inhibitors of this invention are characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting ICE activity and consequently, may be advantageously used as agents against interleukin-1 mediated diseases, including inflammatory diseases, autoimmune diseases and neurodegenerative diseases. This invention also relates to methods for inhibiting ICE activity and methods for treating interleukin-1 mediated diseases using the compounds and compositions of this invention.

  本发明涉及一类新型化合物，其为白细胞介素-1β转化酶抑制剂。本发明的ICE抑制剂具有特定的结构和物理化学特征。本发明还涉及包含这些化合物的药物组合物。本发明的化合物和药物组合物特别适用于抑制ICE活性，因此可以优势地用作对抗白细胞介素-1介导的疾病，包括炎症性疾病、自身免疫性疾病和神经退行性疾病的药物。本发明还涉及使用本发明的化合物和组合物抑制ICE活性的方法和治疗白细胞介素-1介导的疾病的方法。